New Additions to Drugs.com for 2022
The following 50 drugs were added to the Drugs.com database in 2022.
Sunlenca
Dec 27, 2022 - Sunlenca (lenacapavir) is a long-acting HIV-1 capsid inhibitor for use in combination with other antiretroviral(s) for the treatment of HIV-1 infection in heavily treatment-experienced (HTE) adults with multi-drug resistant (MDR) HIV-1 infection.
Krazati
Dec 27, 2022 - Krazati (adagrasib) is an inhibitor of KRASG12C for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC).
Adstiladrin
Dec 19, 2022 - Adstiladrin (nadofaragene firadenovec-vncg) is a non-replicating adenoviral vector-based gene therapy for the treatment of Bacillus CalmetteGuérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC).
Rezlidhia
Dec 7, 2022 - Rezlidhia (olutasidenib) is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.
Rebyota
Dec 2, 2022 - Rebyota (fecal microbiota, live-jslm) is a microbiota-based live biotherapeutic indicated for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older, following antibiotic treatment for recurrent CDI.
Hemgenix
Nov 24, 2022 - Hemgenix (etranacogene dezaparvovec-drlb) is an adeno-associated virus vector-based gene therapy indicated for the treatment of adults with hemophilia B.
Tzield
Nov 18, 2022 - Tzield (teplizumab-mzwv) is a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and pediatric patients aged 8 years and older.
Elahere
Nov 15, 2022 - Elahere (mirvetuximab soravtansine-gynx) is an injectable antibody-drug conjugate that may be used to treat adults with folate receptor-alpha (FRα) -positive platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have already received 1 to 3 prior systemic treatments.
Furoscix
Nov 1, 2022 - Furoscix (furosemide) is a loop diuretic indicated for the treatment of congestion due to fluid overload in adults with NYHA Class II/III chronic heart failure.
Tecvayli
Oct 27, 2022 - Tecvayli (teclistamab) is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager for the treatment of adult patients with relapsed or refractory multiple myeloma.
Imjudo
Oct 25, 2022 - Imjudo is a prescription medicine that may be used in combination with Imfinzi (durvalumab) to treat adults with unresectable hepatocellular carcinoma or non-small cell lung cancer (NSCLC) that has spread (metastatic NSCLC).
Omlonti
Oct 18, 2022 - Omlonti (omidenepag isopropyl) is a relatively selective prostaglandin E2 (EP2) receptor agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Relyvrio
Oct 11, 2022 - Relyvrio (sodium phenylbutyrate and taurursodiol) was a neuroprotective therapy for the treatment of amyotrophic lateral sclerosis (ALS). It has been discontinued.
Skysona
Oct 4, 2022 - Skysona (elivaldogene autotemcel) is a one-time gene therapy used to treat the underlying cause of cerebral adrenoleukodystrophy (CALD).
Rolvedon
Sep 20, 2022 - Rolvedon (eflapegrastim-xnst) is a leukocyte growth factor used to reduce the incidence of infection due to chemotherapy-induced neutropenia.
Sotyktu
Sep 14, 2022 - otyktu (deucravacitinib) is a tyrosine kinase 2 (TYK2) inhibitor indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Daxxify
Sep 14, 2022 - Daxxify (daxibotulinumtoxinA-lanm) is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines in adult patients.
Spevigo
Sep 7, 2022 - Spevigo (spesolimab-sbzo) is an interleukin-36 receptor antagonist indicated for the treatment of generalized pustular psoriasis (GPP) and GPP flares in adults and children 12 years of age and older who weigh at least 40kg.
Auvelity
Aug 22, 2022 - Auvelity (dextromethorphan and bupropion) is an NMDA receptor antagonist for the treatment of major depressive disorder in adults.
Zynteglo
Aug 22, 2022 - Zynteglo (betibeglogene autotemcel) is an autologous hematopoietic stem cell-based gene therapy indicated for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell (RBC) transfusions.
Voquezna Triple Pak
Aug 10, 2022 - Voquezna Triple Pak (amoxicillin, clarithromycin, and vonoprazan) is a co-packaged product containing amoxicillin (penicillin class antibacterial), clarithromycin (macrolide antimicrobial), and vonoprazan (potassium-competitive acid blocker (PCAB)) indicated for the treatment of Helicobacter pylori (H. pylori) infection in adults.
Cimerli
Aug 9, 2022 - Cimerli (ranibizumab-eqrn) is a vascular endothelial growth factor (VEGF) inhibitor, interchangeable biosimilar to Lucentis indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR), and myopic choroidal neovascularization (mCNV).
Kyzatrex
Aug 3, 2022 - Kyzatrex (testosterone undecanoate) is testosterone replacement for the treatment of hypogonadism in adult men.
Zonisade
Aug 1, 2022 - Zonisade (zonisamide) is an oral suspension formulation of the approved anticonvulsant zonisamide indicated as adjunctive therapy for the treatment of partial-onset seizures in adults and pediatric patients 16 years of age and older.
Zoryve
Aug 1, 2022 - Zoryve (roflumilast) is a topical phosphodiesterase 4 (PDE4) inhibitor indicated for the topical treatment of plaque psoriasis.
Amvuttra
Jul 1, 2022 - Amvuttra (vutrisiran) is an RNAi therapeutic for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.
Vtama
May 25, 2022 - Vtama (tapinarof) is a topical aryl hydrocarbon receptor (AhR) modulating agent indicated for the treatment of plaque psoriasis in adults.
Mounjaro
May 17, 2022 - Mounjaro (tirzepatide) is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist for the treatment of type 2 diabetes mellitus in adults.
Camzyos
Apr 30, 2022 - Camzyos (mavacamten) is a cardiac myosin inhibitor indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy.
Vivjoa
Apr 29, 2022 - Vivjoa (oteseconazole) is an oral azole antifungal indicated to reduce the incidence of recurrent vulvovaginal candidiasis.
Epsolay
Apr 27, 2022 - Epsolay (benzoyl peroxide) is a topical oxidizing agent for the treatment of inflammatory lesions of rosacea in adults.
Pluvicto
Apr 13, 2022 - Pluvicto (lutetium lu 177 vipivotide tetraxetan) is a radioligand therapeutic agent indicated for the treatment of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC).
Vijoice
Apr 7, 2022 - Vijoice (alpelisib) is an oral kinase inhibitor indicated for the treatment of adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy.
Hyftor
Apr 5, 2022 - Hyftor (sirolimus topical gel) is an mTOR inhibitor immunosuppressant indicated for the treatment of facial angiofibroma associated with tuberous sclerosis.
Tlando
Mar 30, 2022 - Tlando (testosterone) is an oral testosterone replacement therapy indicated for adult males for conditions associated with a deficiency or absence of endogenous testosterone, also known as hypogonadism.
Xelstrym
Mar 24, 2022 - Xelstrym (dextroamphetamine) transdermal system is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and children 6 years and older.
Ztalmy
Mar 21, 2022 - Ztalmy (ganaxolone) is neuroactive steroid gamma-aminobutyric acid (GABA) A receptor positive modulator indicated for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD).
Opdualag
Mar 21, 2022 - Opdualag (nivolumab and relatlimab-rmbw) is programmed death receptor-1 (PD-1) blocking antibody and lymphocyte activation gene-3 (LAG-3) blocking antibody combination indicated for the treatment of unresectable or metastatic melanoma.
Adlarity
Mar 14, 2022 - Adlarity (donepezil transdermal system) is a once-weekly transdermal formulation of the approved acetylcholinesterase inhibitor donepezil indicated for the treatment of Alzheimer’s type dementia.
Carvykti
Mar 14, 2022 - Carvykti (ciltacabtagene autoleucel) is a BCMA-directed CAR-T immunotherapy for the treatment of patients with relapsed or refractory multiple myeloma.
Vonjo
Mar 7, 2022 - Vonjo (pacritinib) is a JAK2/FLT3 multikinase inhibitor for the treatment of myelofibrosis patients with severe thrombocytopenia.
Bebtelovimab
Feb 23, 2022 - Bebtelovimab is a monoclonal antibody (mAb) for use under EUA in certain non-hospitalized patients with mild-to-moderate COVID-19.
Pyrukynd
Feb 18, 2022 - Pyrukynd (mitapivat) is a pyruvate kinase activator indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency.
Spikevax
Feb 9, 2022 - Spikevax 2023-2024 Formula (COVID-19 Vaccine, mRNA) is a vaccine that may help your body develop immunity to SARS-CoV-2, the virus that causes COVID-19. Spikevax is an FDA-approved vaccine for adults and adolescents aged 12 years and also has emergency use authorization (EUA) for children aged 6 months to 11 years.
Spikevax (Moderna COVID-19 Vaccine)
Feb 9, 2022 - Spikevax (COVID-19 Vaccine, mRNA) is a COVID-19 vaccine for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older.
Enjaymo
Feb 7, 2022 - Enjaymo (sutimlimab-jome) is a classical complement inhibitor indicated to decrease the need for red blood cell (RBC) transfusion due to hemolysis in adults with cold agglutinin disease (CAD).
Kimmtrak
Jan 31, 2022 - Kimmtrak (tebentafusp-tebn) is a bispecific gp100 peptide-HLA-directed CD3 T cell engager indicated for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
Ryaltris
Jan 20, 2022 - Ryaltris (mometasone and olopatadine) nasal spray is a corticosteroid and antihistamine combination for the treatment of seasonal allergic rhinitis (SAR) in patients 12 years of age and older.
Cibinqo
Jan 18, 2022 - Cibinqo (abrocitinib) tablets are used to treat eczema (atopic dermatitis) that is moderate to severe. Cibinqo is a once-a-day tablet that can be used by adults and children over 12 years of age. Cibinqo belongs to a class of medications called JAK inhibitors
Quviviq
Jan 13, 2022 - Quviviq (daridorexant) is a dual orexin receptor antagonist (DORA) for the treatment of insomnia.